Davies et al., 2012 - Google Patents
Identifying and targeting ROS1 gene fusions in non–small cell lung cancerDavies et al., 2012
View PDF- Document ID
- 1091599512841422611
- Author
- Davies K
- Le A
- Theodoro M
- Skokan M
- Aisner D
- Berge E
- Terracciano L
- Cappuzzo F
- Incarbone M
- Roncalli M
- Alloisio M
- Santoro A
- Camidge D
- Varella-Garcia M
- Doebele R
- Publication year
- Publication venue
- Clinical Cancer Research
External Links
Snippet
Purpose: Oncogenic gene fusions involving the 3′ region of ROS1 kinase have been identified in various human cancers. In this study, we sought to characterize ROS1 fusion genes in non–small cell lung cancer (NSCLC) and establish the fusion proteins as drug …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davies et al. | Identifying and targeting ROS1 gene fusions in non–small cell lung cancer | |
| Coates et al. | Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer | |
| Li et al. | Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells | |
| Rimkunas et al. | Analysis of receptor tyrosine kinase ROS1-positive tumors in non–small cell lung cancer: identification of a FIG-ROS1 fusion | |
| Suehara et al. | Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions | |
| Guo et al. | NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer | |
| Ercan et al. | EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors | |
| Magnaghi et al. | Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury | |
| Vaishnavi et al. | EGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinases | |
| Yamamoto et al. | PIK3CA mutations and copy number gains in human lung cancers | |
| Chen et al. | MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | |
| Etemadmoghadam et al. | EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas | |
| Mino-Kenudson | Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? | |
| Doebele et al. | Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer | |
| Cowin et al. | LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin | |
| Yang et al. | Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation | |
| Zhu et al. | Moesin is a glioma progression marker that induces proliferation and Wnt/β-catenin pathway activation via interaction with CD44 | |
| Berns et al. | Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance | |
| Zhong et al. | The RARS–MAD1L1 fusion gene induces cancer stem cell–like properties and therapeutic resistance in nasopharyngeal carcinoma | |
| Eifert et al. | A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis | |
| Shatsky et al. | Next-generation sequencing of tissue and circulating tumor DNA: the UC San Diego Moores Center for personalized cancer therapy experience with breast malignancies | |
| US20220313700A1 (en) | Methods for treating map3k8 positive cancers | |
| Shah et al. | Inhibition of HER2 increases JAGGED1-dependent breast cancer stem cells: role for membrane JAGGED1 | |
| Zhang et al. | Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA | |
| Izumi et al. | Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer |